Latest news with #TLSI
Business Insider
3 days ago
- Business
- Business Insider
TriSalus Life Sciences files to sell 5.5M shares of common stock for holders
17:00 EDT TriSalus Life Sciences (TLSI) files to sell 5.5M shares of common stock for holders Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
16-05-2025
- Business
- Yahoo
TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. TriSalus Life Sciences Inc (NASDAQ:TLSI) reported a 42% increase in net sales for Q1 2025 compared to Q1 2024, demonstrating strong revenue growth. The company achieved significant milestones, including the completion of phase one trials for Nelatolamo, positioning it for potential pharmaceutical partnerships. TLSI expanded its commercial footprint by increasing the number of unique ordering accounts by 39% compared to Q1 2024, adding 32 new accounts. The Centers for Medicare and Medicaid Services issued a new reimbursement code for TriNav, doubling its reimbursable use and supporting broader adoption. TLSI successfully raised approximately $22 million in gross proceeds through a private placement, strengthening its financial position for future investments. Despite revenue growth, TLSI reported operating losses of $7.3 million for Q1 2025, although this was an improvement from the previous year. The company's gross margin decreased slightly to 84% in Q1 2025 from 85% in Q1 2024 due to decreased factory volumes during clean room expansion. TLSI does not anticipate being EBITDA positive or cash flow positive in 2025, as it continues to invest in strategic areas of the business. The company faces challenges in scaling its sales force and ensuring new hires are effectively integrated to drive meaningful volume. There is uncertainty regarding the final data and outcomes from the Nelatolamo trials, which could impact potential partnerships and future revenue. Warning! GuruFocus has detected 5 Warning Signs with TLSI. Q: What should we be looking for in the ero 03 readout, and what would be an attractive outcome for potential partners? A: This was a phase one dose-ranging trial using a novel PEDD device for pancreatic tumors. The device performed well with minimal side effects. The study collected correlative data, including tissue samples and cytokine levels, with secondary endpoints of overall survival. About 50% of the 12 patients are still alive, which is promising. Potential partners are interested in how the drug stimulates the tumor environment and its safety profile. Q: Are you seeing interest in Nelatolamo on its own or in conjunction with TriNav, and how might partnerships be structured? A: Nelatolamo is optimized through our PEDD technology, which allows for direct tumor delivery. The goal is to partner with pharmaceutical companies, handling the procedural aspect and potentially participating on the drug side. PEDD is seen as a platform for delivering various drugs, enhancing tumor concentration while maintaining systemic delivery. Q: What feedback have you received on TriNav Large, and what types of patients and clinicians are adopting it? A: TriNav Large is performing well, particularly for larger tumors and uterine fibroid embolizations. It's used in the liver for tumors fed by larger arteries, such as hepatocellular carcinoma and neuroendocrine tumors. Physicians appreciate its ability to treat larger areas and deliver more drugs faster. Q: How does the clean room expansion impact gross margins, and what should we expect for the rest of the year? A: The clean room expansion was completed in March, negatively impacting gross margins. Now that it's done, margins should improve, trending back to previous levels. We expect margins to be in the upper 80s, potentially reaching 90% in a strong quarter. Q: How does the recent financing and sales force expansion impact revenue growth for the rest of the year? A: The financing allows us to add sales and marketing resources, potentially increasing growth beyond current rates. We plan to add sales resources over the next few months, with significant impact expected in Q4 and more substantial effects in 2026 as new reps gain traction. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Release Date: May 15, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. TriSalus Life Sciences Inc (NASDAQ:TLSI) reported a 42% increase in net sales for Q1 2025 compared to Q1 2024, demonstrating strong revenue growth. The company achieved significant milestones, including the completion of phase one trials for Nelatolamo, positioning it for potential pharmaceutical partnerships. TLSI expanded its commercial footprint by increasing the number of unique ordering accounts by 39% compared to Q1 2024, adding 32 new accounts. The Centers for Medicare and Medicaid Services issued a new reimbursement code for TriNav, doubling its reimbursable use and supporting broader adoption. TLSI successfully raised approximately $22 million in gross proceeds through a private placement, strengthening its financial position for future investments. Despite revenue growth, TLSI reported operating losses of $7.3 million for Q1 2025, although this was an improvement from the previous year. The company's gross margin decreased slightly to 84% in Q1 2025 from 85% in Q1 2024 due to decreased factory volumes during clean room expansion. TLSI does not anticipate being EBITDA positive or cash flow positive in 2025, as it continues to invest in strategic areas of the business. The company faces challenges in scaling its sales force and ensuring new hires are effectively integrated to drive meaningful volume. There is uncertainty regarding the final data and outcomes from the Nelatolamo trials, which could impact potential partnerships and future revenue. Warning! GuruFocus has detected 5 Warning Signs with TLSI. Q: What should we be looking for in the ero 03 readout, and what would be an attractive outcome for potential partners? A: This was a phase one dose-ranging trial using a novel PEDD device for pancreatic tumors. The device performed well with minimal side effects. The study collected correlative data, including tissue samples and cytokine levels, with secondary endpoints of overall survival. About 50% of the 12 patients are still alive, which is promising. Potential partners are interested in how the drug stimulates the tumor environment and its safety profile. Q: Are you seeing interest in Nelatolamo on its own or in conjunction with TriNav, and how might partnerships be structured? A: Nelatolamo is optimized through our PEDD technology, which allows for direct tumor delivery. The goal is to partner with pharmaceutical companies, handling the procedural aspect and potentially participating on the drug side. PEDD is seen as a platform for delivering various drugs, enhancing tumor concentration while maintaining systemic delivery. Q: What feedback have you received on TriNav Large, and what types of patients and clinicians are adopting it? A: TriNav Large is performing well, particularly for larger tumors and uterine fibroid embolizations. It's used in the liver for tumors fed by larger arteries, such as hepatocellular carcinoma and neuroendocrine tumors. Physicians appreciate its ability to treat larger areas and deliver more drugs faster. Q: How does the clean room expansion impact gross margins, and what should we expect for the rest of the year? A: The clean room expansion was completed in March, negatively impacting gross margins. Now that it's done, margins should improve, trending back to previous levels. We expect margins to be in the upper 80s, potentially reaching 90% in a strong quarter. Q: How does the recent financing and sales force expansion impact revenue growth for the rest of the year? A: The financing allows us to add sales and marketing resources, potentially increasing growth beyond current rates. We plan to add sales resources over the next few months, with significant impact expected in Q4 and more substantial effects in 2026 as new reps gain traction. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
26-04-2025
- Business
- Business Insider
TriSalus Life Sciences files to sell 91,263 shares of common stock for holders
17:21 EDT TriSalus Life Sciences (TLSI) files to sell 91,263 shares of common stock for holders Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
